456 related articles for article (PubMed ID: 33645977)
1. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
ACS Infect Dis; 2021 Mar; 7(3):586-597. PubMed ID: 33645977
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
Cell Res; 2020 Aug; 30(8):678-692. PubMed ID: 32541865
[TBL] [Abstract][Full Text] [Related]
3. Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture.
Hu Y; Ma C; Szeto T; Hurst B; Tarbet B; Wang J
bioRxiv; 2020 Nov; ():. PubMed ID: 33140049
[TBL] [Abstract][Full Text] [Related]
4. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
[TBL] [Abstract][Full Text] [Related]
5. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
[TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
[TBL] [Abstract][Full Text] [Related]
7. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
8. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.
Ma C; Sacco MD; Hurst B; Townsend JA; Hu Y; Szeto T; Zhang X; Tarbet B; Marty MT; Chen Y; Wang J
bioRxiv; 2020 Jan; ():. PubMed ID: 32511378
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Activity of Umifenovir In Vitro against a Broad Spectrum of Coronaviruses, Including the Novel SARS-CoV-2 Virus.
Leneva I; Kartashova N; Poromov A; Gracheva A; Korchevaya E; Glubokova E; Borisova O; Shtro A; Loginova S; Shchukina V; Khamitov R; Faizuloev E
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452529
[TBL] [Abstract][Full Text] [Related]
10. Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
Wang Y; Li P; Lavrijsen M; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Arch Virol; 2022 Apr; 167(4):1125-1130. PubMed ID: 35171357
[TBL] [Abstract][Full Text] [Related]
11. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease.
Fu L; Ye F; Feng Y; Yu F; Wang Q; Wu Y; Zhao C; Sun H; Huang B; Niu P; Song H; Shi Y; Li X; Tan W; Qi J; Gao GF
Nat Commun; 2020 Sep; 11(1):4417. PubMed ID: 32887884
[TBL] [Abstract][Full Text] [Related]
12. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell.
Hu Y; Jo H; DeGrado WF; Wang J
J Med Virol; 2022 May; 94(5):2188-2200. PubMed ID: 35080027
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of itraconazole against SARS-CoV-2.
Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
[TBL] [Abstract][Full Text] [Related]
15. Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M
Sacco MD; Ma C; Lagarias P; Gao A; Townsend JA; Meng X; Dube P; Zhang X; Hu Y; Kitamura N; Hurst B; Tarbet B; Marty MT; Kolocouris A; Xiang Y; Chen Y; Wang J
Sci Adv; 2020 Dec; 6(50):. PubMed ID: 33158912
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
Zhu Q; Zhang Y; Wang L; Yao X; Wu D; Cheng J; Pan X; Liu H; Yan Z; Gao L
Antiviral Res; 2021 Mar; 187():105015. PubMed ID: 33444702
[TBL] [Abstract][Full Text] [Related]
17. Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir.
Xia Z; Sacco M; Hu Y; Ma C; Meng X; Zhang F; Szeto T; Xiang Y; Chen Y; Wang J
ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1408-1421. PubMed ID: 34414360
[TBL] [Abstract][Full Text] [Related]
18. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19.
Boras B; Jones RM; Anson BJ; Arenson D; Aschenbrenner L; Bakowski MA; Beutler N; Binder J; Chen E; Eng H; Hammond H; Hammond J; Haupt RE; Hoffman R; Kadar EP; Kania R; Kimoto E; Kirkpatrick MG; Lanyon L; Lendy EK; Lillis JR; Logue J; Luthra SA; Ma C; Mason SW; McGrath ME; Noell S; Obach RS; O' Brien MN; O'Connor R; Ogilvie K; Owen D; Pettersson M; Reese MR; Rogers TF; Rosales R; Rossulek MI; Sathish JG; Shirai N; Steppan C; Ticehurst M; Updyke LW; Weston S; Zhu Y; White KM; García-Sastre A; Wang J; Chatterjee AK; Mesecar AD; Frieman MB; Anderson AS; Allerton C
Nat Commun; 2021 Oct; 12(1):6055. PubMed ID: 34663813
[TBL] [Abstract][Full Text] [Related]
19. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
20. The
Hu Y; Meng X; Zhang F; Xiang Y; Wang J
Emerg Microbes Infect; 2021 Dec; 10(1):317-330. PubMed ID: 33560940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
